Arizona State Retirement System Purchases 1,539 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Arizona State Retirement System boosted its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 3.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 41,069 shares of the biopharmaceutical company’s stock after buying an additional 1,539 shares during the period. Arizona State Retirement System’s holdings in TG Therapeutics were worth $731,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the company. Victory Capital Management Inc. grew its holdings in shares of TG Therapeutics by 24.6% in the second quarter. Victory Capital Management Inc. now owns 26,212 shares of the biopharmaceutical company’s stock valued at $466,000 after purchasing an additional 5,169 shares in the last quarter. Rhumbline Advisers increased its holdings in shares of TG Therapeutics by 7.8% in the 2nd quarter. Rhumbline Advisers now owns 215,055 shares of the biopharmaceutical company’s stock worth $3,826,000 after buying an additional 15,582 shares during the last quarter. nVerses Capital LLC raised its position in shares of TG Therapeutics by 34.9% during the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 1,500 shares in the last quarter. Commonwealth Equity Services LLC increased its stake in TG Therapeutics by 1.3% during the second quarter. Commonwealth Equity Services LLC now owns 186,994 shares of the biopharmaceutical company’s stock worth $3,327,000 after acquiring an additional 2,360 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in shares of TG Therapeutics by 32.3% during the second quarter. Principal Financial Group Inc. now owns 46,817 shares of the biopharmaceutical company’s stock worth $833,000 after acquiring an additional 11,443 shares during the period. Hedge funds and other institutional investors own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on the company. B. Riley lifted their price target on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. HC Wainwright reissued a “buy” rating and issued a $49.00 target price on shares of TG Therapeutics in a report on Tuesday, August 6th. Finally, The Goldman Sachs Group lifted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, TG Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $31.83.

TG Therapeutics Stock Up 2.3 %

TGTX stock opened at $23.73 on Monday. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.58 and a quick ratio of 2.83. The firm has a fifty day moving average price of $21.63 and a two-hundred day moving average price of $18.09. TG Therapeutics, Inc. has a 1-year low of $6.46 and a 1-year high of $25.70. The firm has a market cap of $3.67 billion, a price-to-earnings ratio of 103.17 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. TG Therapeutics had a net margin of 27.60% and a return on equity of 57.73%. The business had revenue of $73.47 million for the quarter, compared to analysts’ expectations of $65.92 million. During the same period in the previous year, the business earned ($0.34) earnings per share. The company’s revenue was up 357.0% on a year-over-year basis. Research analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.